Stacy Smith, MD
Ophthalmology · Salt Lake City, UTNPI 1639348899
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 34.5% of the total. That places this record below the midpoint for ophthalmology clinicians in UT, where the typical reported total is $987.
Across 17 payments — averaging $36.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$213
- Alcon$134
- Apellis Pharmaceuticals, Inc.$122
- Novartis$57
- Genentech USA, Inc.$56
- Kala Pharmaceuticals, Inc.$18
- plus $17 from 1 others
Across 37 payments — averaging $4468.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$64K
- Shire North American Group Inc$61K
- Alcon Research LLC$38K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
What the payments were for
- Food & beverage$61099%
- Education$71%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $213 |
| Alcon | 1 | $134 |
| Apellis Pharmaceuticals, Inc. | 1 | $122 |
| Novartis | 4 | $57 |
| Genentech USA, Inc. | 2 | $56 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Akorn Operating Company LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$617 in reported general payments places this provider in the 35th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 56 | $62,137 |
| LumiganBimatoprost | 50 | $19,983 |
| Cyclosporine | 21 | $9,971 |
| Prednisolone Acetate | 189 | $5,987 |
| IlevroNepafenac | 13 | $4,919 |
| BesivanceBesifloxacin Hcl | 19 | $4,292 |
| Travatan ZTravoprost | 17 | $4,018 |
| Travoprost | 19 | $2,877 |
| Latanoprost | 199 | $2,862 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $2,503 |
| MoxifloxacinMoxifloxacin Hcl | 105 | $2,282 |
| Fluorometholone | 24 | $1,457 |
| Difluprednate | 15 | $1,300 |
| Bromfenac Sodium | 12 | $1,205 |
| Gatifloxacin | 24 | $1,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $213 | $82,120106 claims |
| NovartisIlevro, Travatan Z | $57 | $8,93730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.